[Drugs in Europe]

Area of Science:

• Pharmacovigilance and Regulatory Affairs
• European Union Drug Regulation
• Medicinal Product Authorization

Context:

• A harmonized European system for medicinal product authorization was established in 1995.
• This system involves collaboration between Member State competent authorities, the European Medicines Agency (EMA), and the European Commission.
• Two primary procedures, centralized and mutual recognition, facilitate drug assessment.

Purpose:

• To outline the collaborative framework for European medicinal product authorization.
• To describe the centralized and mutual recognition procedures.
• To identify areas for legislative improvement in drug approval processes.

Summary:

• The European system for authorizing medicinal products since 1995 relies on collaboration among competent authorities, the European Medicines Agency (EMA), and the European Commission.
• Two key procedures, centralized and mutual recognition, assess the efficacy, safety, and quality of new drugs.
• Analysis of these procedures highlights potential areas for legislative enhancement.

Impact:

• Provides a clear overview of the European drug authorization framework.
• Facilitates understanding of the roles of different stakeholders in drug approval.
• Informs future revisions of European pharmaceutical legislation for improved efficiency and effectiveness.